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ABSTRACT 
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids and thus remain buoyant in the stomach for a prolonged 
period of time, without affecting the gastric emptying rate. While the system is floating on the gastric contents, the drug is released slowly at a 
desired rate from the system. These floating tablets mainly prepared for reduction of lag time and release the drug up to 12 hours and may also 
increase the bioavailability of the drugs by utilizing the drug to full extent avoiding unnecessary frequency of dosing. The purpose of this 
research was to develop and evaluated floating matrix tablets of sacubitril and valsartan. The floating matrix tablets of sacubitril and valsartan 
were prepared by direct compression method using altered concentrations of HPMC K4M, HPMC K100M, sodium alginate as polymers and 
sodium bicarbonate, citric acid as gas generating agent. FTIR, DSC studies conformed that there was no incompatibility between the polymers 
and the drug. Tablet preformulation parameters were within the pharmacopoeias limit. Tablets were evaluated by different parameters such as 
weight uniformity, content uniformity, thickness, hardness, in vitro release studies, buoyancy determination and kinetic analysis of dissolution 
data. The varying concentration of gas generating agent and polymers was found to affect on in-vitro drug release and floating lag time. Tablet 
showed ≤ 1min lag time, continuance of buoyancy for >12 h. The in-vitro drug release pattern of sacubitril and valsartan optimized floating 
tablets (F16) was fitted to different kinetic models which showed highest regression (r2 = 0.9838) for Higuchi model. The Optimized 
formulation (F16) showed no significant change in physical appearance, drug content, floating lag time, in vitro dissolution studies after 
75%±5% RH at 40±20C relative humidity for 6 months.  Prepared floating tablets of sacubitril and valsartan may prove to be a potential 
candidate for safe and effective controlled drug delivery over an extended period of time for gastro retentive drug delivery system. 
Keywords: Sacubitril, Valsartan, Floating drug delivery system, HPMC, In vitro release study, Buoyancy determination.  
 
Article Info: Received 09 June 2019;     Review Completed 19 July 2019;     Accepted 20 July 2019;     Available online 15 August 2019  
Cite this article as: 
Pathak S, Pandey H, Shah SK, Formulation and Evaluation of Floating Matrix Tablets of Sacubitril and Valsartan, Journal of 
Drug Delivery and Therapeutics. 2019; 9(4-s):298-309  http://dx.doi.org/10.22270/jddt.v9i4-s.3322                                                
*Address for Correspondence:  
Sudhakar Pathak, Department of Pharmaceutics, College of Pharmacy, Sri Satya Sai University of Technology &Medical 
Sciences, Sehore, Madhya Pradesh, India. 
 
 
INTRODUCTION 
Drugs which are easily absorbed from the gastrointestinal 
tract and those with short half-lives are quickly eliminated 
from the systemic circulation due to which frequent dosing 
is required. To overcome this problem, gastro retentive drug 
delivery systems1. Which provide effective plasma drug 
concentration for longer periods thereby reducing the 
dosing frequency are being formulated2-4. It also has an 
advantage of minimizing the fluctuations in plasma drug 
concentration by delivering the drug in a controlled and 
reproducible manner. Floating drug delivery system or 
hydrodynamically5,6 balanced systems has been reported for 
prolonging the residence time of drug delivery system in a 
particular region of the gastrointestinal tract, were first 
described by Davis (1968)7. The floating of FDDS occurs due 
to their lower bulk density than the gastric contents or due 
to gaseous phase formed inside in the environment. It is 
applicable for those drugs which (i) act locally; (ii) have a 
narrow absorption window in the small intestinal region; 
and (iii) unstable in the intestinal environment8,9. Sacubitril 
is an antihypertensive drug used in combination with 
valsartan10.The combination drug valsartan/sacubitril, 
marketed under the brand name Entresto, is a treatment for 
heart failure11. Sacubitril is a prodrug that is activated to 
sacubitril at by de-ethylation via esterases12. Sacubitrilat 
inhibits the enzyme neprilysin. The most common adverse 
reactions with sacubitril plus valsartan included 
hypotension, hyperkalemia, cough, dizziness, and renal 
failure. Sacubitrilis chemically (S)-5-[(4- phenylphenyl) 
methyl] pyrrolidin-2-one. Sacubitril Slightly soluble in water, 
sparingly soluble in dehydrated alcohol, freely soluble in 
methanol. Valsartan is used to treat high blood pressure, 
congestive heart failure, and to reduce death for people with 
left ventricular dysfunction after having had a heart attack13. 
Valsartan blocks the actions of angiotensin II, which include 
constricting blood vessels and activating aldosterone, to 
reduce blood pressure14. The drug binds to angiotensin type 
I receptors (AT1), working as an antagonist. This mechanism 
of action is different than the ACE inhibitor drugs, which 
Pathak et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):298-309 
ISSN: 2250-1177                                                                                  [299]                                                                                 CODEN (USA): JDDTAO 
block the conversion of angiotensin I to angiotensin II. Since 
valsartan acts at the receptor, it can provide more complete 
angiotensin II antagonism since angiotensin II is generated 
by other enzymes as well as ACE. Most common side effects 
include dizziness, low blood pressure, and diarrhea. 
Valsartan is chemically (2S)-3-methyl-2-(N-{[2’-(2H- 1,2,3,4-
tetrazole-5-yl)biphenyl-4-yl]methyl}pentanamid o) butanoic 
acid. Valsartan soluble in acetonitrile, practically insoluble in 
water also soluble in methanol. The present study aims in 
designing floating tablets of sacubitril and valsartan using 
HPMC K4M, HPMC K100M, sodium alginate, sodium 
bicarbonate, citric acid and evaluating the prepared tablets.  
MATERIALS AND METHODS  
Materials  
Sacubitril, Valsartan was obtained as a gift sample from 
Torrent Research Centre, Ahmedabad. HPMC K4M, HPMC 
K100M, sodium alginate, sodium bicarbonate, citric acid was 
obtained from ACS Chemicals, Ahmedabad. Magnesium 
stearate, DCP, Talc, were received from S D fine Chemicals, 
Mumbai. India. All other solvents and reagents were 
purchased from Merck (Germany) and were of analytical 
grade. All the studies were carried in distilled water. 
Methods 
Determination of absorption maxima  
A solution of containing the concentration 15and 40μg/ml 
was prepared in 0.1N HCl (1.2 pH). UV spectrum was taken 
using Double beam UV/VIS spectrophotometer (Shimdzu 
Jappan). The solution was scanned in the range of 200-
400nm.  
Preparation calibration curve of Valsartan 
100mg of drug was accurately weighed and dissolved in 
100ml 0.1N HCl (1.2 pH) in 10 ml volumetric flask, to make 
(1000 μg/ml) standard stock solution (1). Then 10 ml stock 
solution (1) was taken in another 100 ml volumetric flask to 
make (100μg/ml) standard stock solution (2), then again 
0.5, 1, 1.5, 2, 2.5,3 and 3.5 ml of stock solution (2) was taken 
in another 10 ml volumetric flask and then final 
concentrations were prepared 5, 10, 15, 20, 25,30 and 
35μg/ml with 0.1N HCl (1.2 pH). The absorbance of standard 
solution was determined using UV/ VIS spectrophotometer 
(Shimdzu Jappan) at 238nm. Linearity of standard curve was 
assessed from the square of correlation coefficient (r2) 
which determined by least-square linear regression analysis. 
Preparation calibration curve of Sacubitril  
100mg of drug was accurately weighed and dissolved in 
100ml 0.1N HCl (1.2 pH) in 10 ml volumetric flask, to make 
(1000 μg/ml) standard stock solution (1). Then 10 ml stock 
solution (1) was taken in another 100 ml volumetric flask to 
make (100μg/ml) standard stock solution (2), then again 
1,2,3,4,5,6 and7ml of stock solution (2) was taken in another 
10 ml volumetric flask and then final concentrations were 
prepared 10,20,30,40,50,60 and 70μg/ml with 0.1N HCl (1.2 
pH). The absorbance of standard solution was determined 
using UV/ VIS spectrophotometer (Shimdzu Jappan) at 
266nm. Linearity of standard curve was assessed from the 
square of correlation coefficient (r2) which determined by 
least-square linear regression analysis. 
Drug -excipient compatibility studies 
Fourier Transform Infrared (FTIR) spectroscopy 
Before formulating a dosage form it is very necessary to 
confirm that drug is not interacting with the polymer under 
certain experimental studies. Interacting among drug and 
polymer may affect the efficacy of final dosage form. The 
infrared spectra of pure drug and with excipients (1:1) was 
recorded between 600 and 4000 cm−1 by Fourier-transform 
infrared (FT-IR) spectrometer (Bruker, USA) using the 
potassium bromide pellet technique. 
DSC Study 
Assessment of possible incompatibilities between an active 
drug substance and different excipients forms an important 
part of the Preformulation stage during the development of 
dosage form. Differential Scanning Calorimeter allows the 
fast evaluation of possible incompatibilities, because it 
shows changes in the appearance, shift of melting 
endotherms and exotherms, and/or variations in the 
corresponding enthalpies of reaction. The DSC thermograms 
of pure drug, other excipients and optimized batch were 
recorded. 
Pre compression evaluation 
Flow properties and compressibility properties of powder 
mixture were evaluated by measurement of angle of repose, 
bulk density, tapped density, carr’s index, and hausner ratio. 
Angle of repose (θ) 
The angle of repose was determined by using fixed funnel 
method. The physical mixtures of drug with different 
excipients were prepared and the accurately weighed drug 
powder or its physical mixture was taken in a funnel. The 
height of the funnel was adjusted in such a way that the tip 
of the funnel just touches the apex of the heap of the drug 
powder. The powder was allowed to flow through the funnel 
freely onto surface. The angle of repose was calculated using 
the following equation.            θ = tan-1(h/r) 
Where, h and r are the height and radius of the powder cone 
respectively. 
Bulk density 
Both loose bulk density (LBD) and tapped density (TBD) 
were determined were calculated using the following 
formulas. 
LBD = Powder weight/volume of the packing 
TBD = Powder weight /tapped volume of the packing 
Compressibility index 
 The compressibility index of the granules was determined 
by Carr’s compressibility index. 
Carr’s index (%) = [(TBD – LBD)/TBD] × 100. 
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of measuring the 
powder flow. It was calculated by the following formula15,16. 
Hausner’s ratio = Tapped density/Bulk density. 
Formulation development of Tablets 
Direct compression method 
Preliminary Trials (For selection of polymer) 
Composition of preliminary trials for selection of polymer 
was shown in Table 1. Tablets containing different matrix 
forming agent were prepared by direct compression 
technique. All the powders were passed through 40 mesh 
sieves. Required quantity of drug and various ingredients 
like matrix forming agent, gas generating agent and diluents 
were mixed thoroughly. Talc and magnesium stearate were 
finally added as glidant and lubricant respectively. The blend 
was compressed using tablet press machine.  
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Table 1 Selection of polymer 
Ingredients (mg) F1 F2 F3 F4 F5 F6 
Sacubitril 24 24 24 24 24 24 
Valsartan 26 26 26 26 26 26 
HPC K4M 80 - - 30 - - 
HPMC K100M - 80 - - 30 - 
Sod. Alginate - - 80 - - 30 
Sod. Bicarbonate 20 20 20 20 20 20 
Citric Acid 10 10 10 10 10 10 
DCP 64 64 64 114 114 114 
Talc 2 2 2 2 2 2 
Mg. stearate 4 4 4 4 4 4 
Total weight 230 230 230 230 230 230 
 
Optimization of concentration of HPMC K100M as 
matrixing agent 
The result of preliminary trials revealed that HPMC K100M 
as a matrixing agent gives satisfactory results. Hence HPMC 
K100M was used in different concentrations of 25-10%, 
along with drug. Composition of different batches is shown 
in Table 2 
 
Table 2 Determination of polymer (HPMC K100M) concentration 
Ingredients (mg) F7 F8 F9 F10 
Sacubitril 24 24 24 24 
Valsartan 26 26 26 26 
HPMC K100 M 50 40 30 20 
Sod. Bicarbonate 20 20 20 20 
Citric Acid 10 10 10 10 
DCP 94 104 114 124 
Talc  2 2 2 2 
Mg. stearate 4 4 4 4 
Total weight 230 230 230 230 
 
Selection of Gas generating agent using HPMC K100M as 
matrixing agent 
Composition for selection of gas generating agent was 
shown in Table 3. In this formula two different gas 
generating agents like sodium bicarbonate and calcium 
carbonate were selected in same concentration. 
Table 3 Effect of different gas generating agents on 
drug release profile 
Ingredients (mg) F11 F12 
Sacubitril 24 24 
Valsartan 26 26 
HPMC K100M 30 30 
Sod. Bicarbonate 20 - 
Ca. carbonate - 20 
Citric Acid 10 10 
DCP 114 114 
Talc 2 2 
Mg. stearate 4 4 
Total weight 230 230 
 
Optimization of the concentration of sodium bicarbonate 
as a Gas generating agent  
For optimization of gas generating agent, different 
concentration of sodium bicarbonate 7.5%, 10% and 12.5% 
should be taken which is shown in Table 4. The effect of 
concentration of gas generating agent was to be evaluated. 
Table 4 Optimized the concentration of Gas generating 
agent 
Ingredients (mg) F13 F14 F15 
Sacubitril 24 24 24 
Valsartan 26 26 26 
HPMC K100 M 30 30 30 
Sod. Bicarbonate 15 20 25 
Citric Acid 10 10 10 
DCP 129 114 119 
Talc  2 2 2 
Mg. stearate 4 4 4 
Total weight 230 230 230 
 
Selection of diluents using release profile of HPMC K100M 
floating matrix tablets 
To selection of diluents using the release profile of floating 
matrix tablet from different formulation batches containing 
lactose (water soluble) and dicalcium phosphate (DCP) 
(water insoluble) were formulated Table 5.  
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Table 5 Selection of diluents 
Ingredients (mg) F16 F17 
Sacubitril 24 24 
Valsartan 26 26 
HPMC K100M  30 30 
Sod. Bicarbonate 20 20 
Citric Acid 10 10 
DCP 114 - 
Lactose - 114 
Talc  2 2 
Mg. stearate 4 4 
Total weight 230 230 
 
Evaluation of tablets 
All the tablets were evaluated for following various 
parameters which includes. 
Weight variation test  
To study weight variation 20 tablets of the formulation were 
weighed using a Sartorius electronic balance.  
Hardness  
The hardness of five tablets was determined using the 
Monsanto hardness tester and the average values were 
calculated. 
Thickness 
The thickness of the tables was determined by using Vernier 
calipers. Five tablets were used, and average values were 
calculated. 
Tablet friability 
The friability of the tablets was measured in a Roche 
friabilator (Camp-bell Electronics, Mumbai). Tablets of a 
known weight (W0) or a sample of 10 tablets are dedusted in 
a drum for a fixed time (100 revolutions) and weighed (W) 
again. Percentage friability was calculated from the loss in 
weight as given in equation as below.  The weight loss 
should not be more than 1 %. Determination was made in 
triplicate. 
%Friability= W0-W/ W ×100 
Drug content 
Five tablets were weighed individually, and the drug was 
extracted in 0.1 N HCl, filter through 0.45 membrane. The 
absorbance was measured at 238 and 266 nm after suitable 
dilution using a Shimadzu UV-1700 UV/Vis double beam 
spectrophotometer. 
In vitro buoyancy studies  
The in vitro buoyancy was determined by using dissolution 
testing apparatus USP type-1. The tablets were placed in 900 
ml 0.1 N HCL at 100 rpm basket rotation at 37±0.5ºc. The 
time require for tablets to ascend to the surface of 
dissolution medium and time taken by tablet to buoyant on 
surface of medium was recorded as floating lag time and 
total floating time.  
Swelling index    
The swelling index of tablets was in 0.1 N HCL. Tablets were 
weighed individually named as W0 and then it is placed in 
separately in glass beaker containing 200 ml 0.1N HCL at 
37±0. 5ºC. At periodical time interval tablets were removed 
from beaker and extra amount of surface water discarded by 
blotting paper and then tablets were weighed and it is 
referred as Wt and swelling index was calculated using 
following formula:  
Swelling index = Wt – W0  
                                   W0                                                              
 where Wt = weight after swelling 
 W0 = weight before swelling 
Where, W0 is the initial weight of tablet, and Wt is the weight 
of the tablet at time t. 
Content uniformity 
Randomly selected 10 tablets were weighed and make 
powdered individually. Take powder of individual tablet 
which is equivalent to 500 mg was weighed and dissolve in 
100 ml of methanol, then the solution was sonicated for 15 
min, then undissolved matter was removed by filtration. The 
absorbance of the diluted solutions is measured at 238 and 
266 nm. 
In Vitro dissolution studies 
USP apparatus II was used to test the dissolution profile 
using 900 ml of 0.1N HCl as dissolution medium at 50 rpm 
and 37◦C ± 0.5◦C. six tablets from each batch were placed 
into respective basket containing HCl. 10ml of the sample 
was withdrawn hourly for 8h. The sample was filtered and 
from the filtrate 3ml was withdrawn. The volume was 
adjusted to 100ml with 0.1N HCl in the 100 ml to prepare 10 
mcg/ml solutions. Absorbance of the solution was measured 
using UV spectrophotometer at 238 and 266 nm. 
Drug release kinetic study 
 Data obtained form in vitro drug release studies were fitted 
to disso calculation software. The kinetic models used are 
zero order, first order, Korshmers and papps, Hexon crowell, 
and Higuchi equation. 
The rate and mechanism of release of Drug from the 
prepared tablets were analyzed by fitting the dissolution 
data into the zero-order equation: 
Q = k0t 
Where, Q is the amount of drug released at time t, k0 is the 
release rate constant. The dissolution data fitted to the first 
order equation: 
ln (100–Q) = ln 100 – K1 t  
Where, k1 is the release rate constant. The dissolution data 
was fitted to the Higuchi’s equation: 
Q = k2 t1/2  
Where, k2 is the diffusion rate constant. 
The dissolution data was also fitted to Korsmeyer equation, 
which is often used to describe the drug release behavior 
from polymeric systems: 
Log (Mt/M∞) = log k + n log t  
Where Mt is the amount of drug released at time t, M∞ is the 
amount of drug release after infinite time, K is a release rate 
constant incorporating structural and geometric 
characteristics of the tablet, n is the diffusion exponent 
indicative of the mechanism of drug release17-19. 
Stability study 
Optimized batch of prepared floating tablet subjected to 
accelerated stability studies at 40 °C and 75% RH for 1 
month in a humidity chamber. The tablets of best batch were 
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packed in aluminum foil pouch and analyzed for floating 
behavior and in-vitro drug release study. 
RESULTS AND DISCUSSION 
Sacubitril was found to be White to off-white solid powder in 
appearance, Characteristic odour and tasteless. Sacubitril 
was freely soluble in 0.1N HCL and distilled water. Valsartan 
was found to be white to practically white fine powder in 
appearance, Characteristic odour and was freely soluble in 
0.1N HCL and distilled water. The IR spectra of the pure drug 
and the optimized formulation showed in figure 1 and 2. 
From the figure, it concluded that there was no any 
interaction between drug and excipients found. 
 
 
Figure 1 FT-IR Spectrum of Sacubitril and Valsartan 
 
Figure 2 FT-IR Spectrum of optimized Formulation (F16) 
 
The DSC thermograms of the Sacubitril and Valsartan are 
shown in below figure 3 and 4 individually. Figure 5 shows 
DSC thermogram of the final formulation (F16). From the 
DSC Thermogram it concluded that no any drug excipients 
interaction observed and formulation excipients found 
compatible with drugs. 
  
 
Figure 3 DSC Thermogram of Valsartan 
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 Figure 4 DSC Thermogram of Sacubitril 
 
 Figure 5 DSC Thermogram of Final Formulation (F16) 
The calibration curve of Sacubitril and Valsartan was found to be linear in the concentration range of 10-70 and 5-35µg/ml at 
266 and 238nm respectively figure 6, 7. 
 
Figure 6 Calibration curve of Sacubitril in 0.1 N HCl at 266 nm 
 
Figure 7 Calibration curve of Valsartan in 0.1 N HCl at 238 nm 
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Tablet powder blend was subjected to various pre-
formulation parameters Table 6. From the below table we 
found that bulk density found between 0.42-0.57g/ml and 
tapped density found between 0.49-0.64 g/ml. Hausner’s 
ratio value is less than 1.25 for all formulation means all the 
formulation has good flow properties. And it favors to do 
with direct compression method for tablet preparation.
 
Table 6 Pre-Compression Parameters of Formulation F1-F17 
Formulation 
Bulk density 
(g /ml) (n=3) 
Tapped density 
(g /ml) (n=3) 
Carr’s index 
(%) 
Hausner’s 
ratio 
Angle of repose 
(θ°) (n=3) 
F1 0.54 ± 0.02 0.61 ± 0.03 11.48 ± 0.01 1.13 ± 0.02 17.25 ± 0.05 
F2 0.48 ± 0.03 0.52 ± 0.05 7.69 ± 0.02 1.08 ± 0.01 19.22 ± 0.08 
F3 0.47 ± 0.05 0.55 ± 0.03 14.55 ± 0.04 1.17 ± 0.02 21.12 ± 0.07 
F4 0.57 ± 0.07 0.60 ± 0.04 5.00 ± 0.07 1.05 ± 0.01 19.26 ± 0.08 
F5 0.47 ± 0.04 0.54 ± 0.04 12.96 ± 0.05 1.15 ± 0.02 25.15 ± 0.07 
F6 0.42 ± 0.05 0.54 ± 0.02 16.00 ± 0.06 1.19 ± 0.02 21.15 ± 0.05 
F7 0.51 ± 0.08 0.56 ± 0.05 8.93 ± 0.04 1.10 ± 0.01 19.56 ± 0.04 
F8 0.52 ± 0.02 0.58 ± 0.04 10.34 ± 0.05 1.12 ± 0.01 18.75 ± 0.03 
F9 0.47 ± 0.04 0.54 ± 0.02 12.96 ± 0.05 1.15 ± 0.01 17.84 ± 0.03 
F10 0.58 ± 0.03 0.65 ± 0.03 10.77 ± 0.02 1.12 ± 0.01 19.29 ± 0.05 
F11 0.49 ± 0.04 0.58 ± 0.08 15.52 ± 0.03 1.18 ± 0.02 22.14 ± 0.08 
F12 0.47 ± 0.05 0.54 ± 0.08 12.96 ± 0.04 1.15 ± 0.02 21.04 ± 0.07 
F13 0.48 ± 0.06 0.59 ± 0.07 18.64 ± 0.02 1.23 ± 0.01 18.56 ± 0.05 
F14 0.58 ± 0.05 0.64 ± 0.05 9.38 ± 0.03 1.10 ± 0.01 17.45 ± 0.06 
F15 0.48 ± 0.04 0.53 ± 0.06 9.43 ± 0.05 1.10 ± 0.02 16.84 ± 0.04 
F16 0.43 ± 0.03 0.49 ± 0.04 12.24 ± 0.06 1.14 ± 0.01 19.84 ± 0.06 
F17 0.46 ± 0.07 0.52 ± 0.07 11.54 ± 0.02 1.13 ± 0.01 21.54 ± 0.04 
 
In process test for tablets should be performed for 
acceptance of batches. All batches were performed IPQC test 
like weight variation, Drug content, Hardness and Thickness. 
Optimized batch F16 passed all the specified range of 
parameter. F16 batch was shown weight variation in the 
range of 230 ± 3.5 mg. It had also sufficient hardness to 
stand mechanical shock. Friability of batch F16 was 
0.65±0.17 % which was desirable for our formulation Table 
7, 8. 
 
Table 7  Evaluation parameter of tablets 
Batch 
Weight variation test 
(mg) 
Thickness 
(mm) 
(n=3) 
Hardness 
(kg/cm2) 
Friability (%) 
F1 235 ± 2.82 4.51±0.09 4.8 ± 0.12 0.84 ± 0.14 
F2 230 ± 2.57 4.49±0.11 4.5 ± 0.05 0.70 ± 0.29 
F3 230 ± 3.51 4.50±0.12 4.5 ± 0.06 0.73 ± 0.18 
F4 230 ± 2.54 4.52±0.11 5 ± 0.15 0.61 ± 0.24 
F5 225 ± 2.74 4.51±0.11 5 ± 0.13 0.62 ± 0.24 
F6 230 ± 2.62 4.48±0.13 5.5 ± 0.05 0.77 ± 0.16 
F7 230 ± 3.59 4.52±0.14 5 ± 0.15 0.82 ± 0.11 
F8 235 ± 2.88 4.51±0.12 6 ± 0.11 0.84 ± 0.15 
F9 230 ± 2.56 4.51±0.10 5 ± 0.14 0.70 ± 0.29 
F10 225 ± 2.86 4.50±0.13 4.5 ± 0.03 0.73 ± 0.18 
F11 233 ± 2.34 4.49±0.14 5 ± 0.16 0.61 ± 0.24 
F12 231 ± 3.51 4.47±0.08 6 ± 0.19 0.68 ± 0.14 
F13 229 ± 3.88 4.51±0.09 4.5 ± 0.06 0.65 ± 0.13 
F14 230 ± 2.54 4.48±0.11 6 ± 0.11 0.54 ± 0.21 
F15 226 ± 2.88 4.47±0.06 5 ± 0.12 0.81 ± 0.15 
F16 230 ± 3.54 4.49±0.11 5.6 ± 0.2 0.65 ± 0.17 
F17 231 ± 2.46 4.52±0.14 4.5 ± 0.06 0.73 ± 0.16 
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Table 8 Post Compression Parameters of Formulation F1-F17 
Formulation 
Drug Content 
of Sacubitril 
(%) 
(n=3) 
Drug Content 
of Valsartan 
 (%) 
(n=3) 
Swelling 
Index 
(%) 
(n=3) 
Floating Lag 
Time (sec) 
 
Total Floating 
Time (hr) 
 
F1 99.2 ± 0.3 99.4 ± 0.4 58.2 ± 4.4 840 sec > 10 hrs. 
F2 99.8 ± 0.4 98.5 ± 0.5 62.5 ± 2.2 35 sec > 12 hrs. 
F3 98.5 ± 0.5 99.5 ± 0.7 54.6 ± 5.3 30 sec > 6 hrs. 
F4 97.8 ± 0.7 97.8 ± 0.5 51.6 ± 6.2 45 sec > 8 hrs. 
F5 99.5 ± 0.5 99.8 ± 0.6 62.4 ± 4.3 19 sec > 12 hrs. 
F6 99.4 ± 0.4 99.4 ± 0.5 68.5 ± 5.2 105 sec > 6 hrs. 
F7 99.5 ± 0.5 98.4 ± 0.4 72.1 ± 1.6 35 sec > 12 hrs. 
F8 99.7 ± 0.6 99.4 ± 0.2 68.6 ± 3.2 43 sec > 12 hrs. 
F9 98.4 ± 0.4 98.8 ± 0.4 69.4 ± 2.5 40 sec > 12 hrs. 
F10 100.5 ± 0.5 99.7 ± 0.2 68.5 ± 3.2 50 sec > 12 hrs. 
F11 100.8 ± 0.4 99.9 ± 0.6 67.4 ± 3.6 20 sec > 12 hrs. 
F12 98.7 ± 0.2 99.8 ± 0.4 66.5 ± 5.6 22 sec > 12 hrs. 
F13 99.5 ± 0.3 99.4 ± 0.5 69.7 ± 3.9 25 sec > 12 hrs. 
F14 98.6 ± 0.4 99.7 ± 0.7 78.5 ± 2.9 20 sec > 12 hrs. 
F15 99.7 ± 0.5 98.7 ± 0.5 71.5 ± 3.4 19 sec > 12 hrs. 
F16 99.8 ± 0.5 99.6 ± 0.8 85.6 ± 5.6 17 sec > 12 hrs. 
F17 98.7 ± 0.4 98.9 ± 0.4 74.1 ± 4.5 20 sec > 12 hrs. 
   
In Vitro drug release study 
Preliminary Trials (For selection of polymer) 
For preliminary trial, three different matrixing agents were 
used, at different concentration level as indicated in Table 1. 
The polymers were taken HPC HXF (Klucel) (F1), HPMC 
K100M (F2) and Sodium alginate (F3) as matrixing agent and 
sodium bicarbonate as gas generating agent. In all among 
these batches, when 40% concentration of polymer was used 
then drug release from matrix was much sustained. Drug 
release after 12 hours in HPC HXF (Klucel), HPMC K100M 
and Sodium alginate is 46.27%, 84.23% and 72.32% 
respectively.  Therefore, it was required to decrease the 
concentration of each of the polymers. Decreasing 
concentration up to 15% of each matrixing agent, drug 
release was evaluated. Batches F4 - F6 were prepared and 
dissolution was taken in 0.1N HCl in Type II dissolution 
apparatus in 50 RPM at 37.5oC. From these batches, HPMC 
K100M matrix shows best release profile which is more 
similar to the calculated theoretical profile as compare to 
other polymers. Drug release after 12 hours was 93.46% 
which was suitable for our formulation. Effect of different 
matrixing agent on floating lag time also determined. Tablets 
containing HPC polymer lost their shape due to their more 
swelling property. And in case of sodium alginate floating lag 
time was higher as compared to HPMC K100M batches 
therefore; they were not suitable for our formulation. F5 
batch which has matrixing agent HPMC K100M gives floating 
lag time of only 15 sec., which is lower as compared to other 
and desirable for best formulation. So, from the preliminary 
study, we selected HPMC K100M as a matrixing agent for our 
formulation Figure 8, 9. 
 
 
Figure 8 In-Vitro Drug release of Sacubitril in Preliminary Trials 
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Figure 9 In-Vitro Drug release of Valsartan in Preliminary Trials 
 
Optimization of concentration of HPMC K100M as 
matrixing agent 
From the Table 2, different concentrations of HPMC K100M 
were taken as matrixing agents.  For optimizing the 
concentration of polymer, concentration of HPMC K100M 
taken were from 25% to 10% in decreasing order. In this 
study, it was observed that when decreasing the 
concentration of polymer drug release increased and 
floating lag time decreased. Observed that when increasing 
concentration of matrixing agent drug release sustained. 
Thus, observed data show same result. From this data batch 
F9 shows 89.43% drug release after 12 hours and floating 
lag time is 20 sec. considering the similarity factor, batch F9 
is best suitable for our preparation. Similarity factor f2 value 
of batch F9 was >>50 (i.e 64.02). Drug release profile of 
different concentrations of HPMC K100M is shown in figure 
10, 11. 
 
 
Figure 10 In-Vitro Drug release of Sacubitril 
 
Figure 11 In-Vitro Drug release of Valsartan 
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Selection of Gas generating agent using HPMC K100M as 
matrixing agent 
The composition of formula for selection of gas generating 
agent in gastro retentive drug delivery system. The effect of 
gas generating agent on drug release profile was checked out 
by taking different gas generating agent like sodium 
bicarbonate and calcium carbonate in 10% concentration. 
There is no significant difference between the effect of 
sodium bicarbonate and calcium carbonate on release 
profile. However, this study observed that sodium 
bicarbonate has higher gas generating efficiency than 
calcium carbonate. The drug release profile of these batches 
showed that sodium bicarbonate (batch F11) release up to 
92.13% drug whereas in calcium carbonate (batch F12) 
showed 84.27% drug release after 12 hours. There is no 
significant effect on floating lag time of optimized tablets. But 
when considering Similarity factor (f2) of F11 and F12 
batches has 68.56 and 58.07 which showed that sodium 
bicarbonate is more suitable for our formulation.  So, sodium 
bicarbonate is selected for our formulation. 
Optimized the concentration of sodium bicarbonate as a 
Gas generating agent  
The effect of concentration of sodium bicarbonate on drug 
release profile was checked out on formulations containing 
approximately 7.5%, 10 % and 12.5% of the gas generating 
agent. The drug release in the first hour for all the three 
batches F13, F14 and F15 was approx. near to 33 % and that 
after 12 hours was near to 95% (> 90%). The similarity 
factor for batches F13, F14 and F15 in ascending order of 
batch numbers was 63.39, 67.86 and 58.03 respectively. 
During the in vitro buoyancy test, a significant change was 
observed in the floating lag time of the formulation with 
increased amount of sodium bicarbonate. With increase in 
concentration of sodium bicarbonate floating lag time 
decreased. Desired floating of the tablets was not achieved in 
lower concentrations of sodium bicarbonate. The FLT for 
formulation batch F14 was 20 seconds, which contained 
approx. 10% concentration of sodium bicarbonate. The FLT 
and drug release after 12 hours of batch F14 was very close 
to the desired objective and also to that of batch F15. 
Evaluating all these parameters, batch A14 was selected as 
the optimized batch since it gives best release profile as 
compare to theoretical profile (FLT: approximately 20 
seconds) and having similarity factor greater than 50. Thus, 
from drug release profile, 10% concentration of sodium 
bicarbonate was optimum. 
Selection of diluents using release profile of HPMC K100M 
floating matrix tablets 
For selection of diluents, water-soluble (lactose) (F17) and 
water-insoluble (DCP) (F16) fillers should be used. There 
were no differences between the two different fillers. But 
from the point of view of directly compressible method, DCP 
was best suitable because of their good flow property and 
compressibility. The slight increase in drug release in DCP 
can probably be explained by the less tight hydrogel 
structures upon swelling. There were same results predicted 
in our investigation. Thus, DCP should be taken as filler for 
further investigation due to their good flow property and 
compressibility Figure 12, 13. 
 
 
Figure 12 In-Vitro Drug release of Sacubitril 
 
Figure 13 In-Vitro Drug release of Valsartan 
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All the different formulation had floating lag time less than 2 
minutes. The pictorial results of in vitro buoyancy study of 
the best batch are shown in figure 14, which clearly depicts 
the floating lag time, stable and persistent buoyancy and 
swelling characteristic of tablet. 
 
           
At initial time                       after 17 seconds                              after 12 hours 
Figure 14 in vitro buoyancy studies of batch F16 
The dissolution profile of the best batch (F16) was fitted to 
zero-order, first-order, Higuchi and korsmeyer models to 
ascertain the kinetic modeling of drug release. It may be 
concluded that the drug release from gastro retentive 
floating tablet is best explained by Higuchi model because R2 
value of Higuchi model has 0.9838. The values of slope and 
intercept for Higuchi model are 18.517 and 5.5844 
respectively Table 9. 
 
Table 9   Kinetic modeling data of batch F16 
Model Zero-order First-order Higuchi plot Korsmeyer 
R2 0.896 0.3542 0.9838 0.9636 
Slope 3.2971 0.0399 18.517 0.3062 
Intercept 25.81 1.2756 5.5844 1.4652 
 
CONCLUSION 
The present investigation aimed that preparation of twice 
daily formulation and for that the HPMC K100M was 
optimized as matrixing agent in hydrophilic matrix tablets. 
HPMC K100M has low density than release media i.e. 0.1N 
HCl. Incorporation of the gas generating agent like sodium 
bicarbonate helps to floating tablets. Tablets have floating 
behavior for 12 hrs. It is possible due to high viscosity of 
HPMC K100M. The drug release from the matrix is Biphasic. 
In this, immediate drug release from matrix for first hour and 
after that drug release is controlled by the HPMC matrix for 
12 hours. HPMC swell and controlled drug release. By 
evaluating different concentration of HPMC K100M, 15% 
concentration gives more nearer to desired profile. Floating 
lag time of this batch has only 17 sec and tablet float for 
more than 12 hours. So, it is suitable for our formulation. 
Faster release of the drug during first hour was due to faster 
release of drug from the surface of the hydrophilic matrix 
tablet and after that drug release was diffusion controlled. 
Drug diffuses out from the hydrophilic matrix of HPMC 
K100M for 12 hours. So, finally obtained batch which is 
suitable for our experiment have 30 mg HPMC K100M, 20 mg 
Sodium bicarbonate, 114 mg DCP and required quantity of 
glidant and lubricant.  
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